Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2025)

Amylyx Pharmaceuticals has reported Non Operating Income over the past 5 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$5.0 million for Q4 2025, down 135.44% from a year ago — trailing twelve months through Dec 2025 was -$2.0 million (down 108.13% YoY), and the annual figure for FY2024 was $12.6 million, up 2008.33%.
  • Non Operating Income for Q4 2025 was -$5.0 million at Amylyx Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over the last five years, Non Operating Income for AMLX hit a ceiling of $14.0 million in Q4 2024 and a floor of -$11.6 million in Q4 2023.
  • Median Non Operating Income over the past 5 years was $43000.0 (2021), compared with a mean of $733250.0.
  • Biggest five-year swings in Non Operating Income: crashed 2989.83% in 2022 and later soared 4527.16% in 2024.
  • Amylyx Pharmaceuticals' Non Operating Income stood at -$59000.0 in 2021, then crashed by 2989.83% to -$1.8 million in 2022, then tumbled by 537.03% to -$11.6 million in 2023, then soared by 220.26% to $14.0 million in 2024, then tumbled by 135.44% to -$5.0 million in 2025.
  • The last three reported values for Non Operating Income were -$5.0 million (Q4 2025), $1.6 million (Q3 2025), and -$546000.0 (Q2 2025) per Business Quant data.